Albany Molecular Research Inc Stock Upgraded (AMRI)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Albany Molecular Research (Nasdaq: AMRI) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • The current debt-to-equity ratio, 0.50, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 5.99, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to its closing price of one year ago, AMRI's share price has jumped by 53.09%, exceeding the performance of the broader market during that same time frame. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
  • ALBANY MOLECULAR RESH INC's earnings per share declined by 47.6% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ALBANY MOLECULAR RESH INC turned its bottom line around by earning $0.40 versus -$0.12 in the prior year. This year, the market expects an improvement in earnings ($0.82 versus $0.40).
  • 35.20% is the gross profit margin for ALBANY MOLECULAR RESH INC which we consider to be strong. Regardless of AMRI's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 5.90% trails the industry average.
  • AMRI, with its decline in revenue, underperformed when compared the industry average of 19.2%. Since the same quarter one year prior, revenues slightly dropped by 0.1%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Albany Molecular Research has a market cap of $545 million and is part of the health care sector and drugs industry. Shares are up 71.4% year to date as of the close of trading on Wednesday.

You can view the full Albany Molecular Research Ratings Report or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Insider Trading Alert - MGRC, GUID And AMRI Traded By Insiders

Insider Trading Alert - NTGR, SCOR And AMRI Traded By Insiders